At a Glance
- Companies: Insilico Medicine; Qilu Pharmaceutical Group
- Location: Cambridge, MA, USA (Insilico); Jinan, China (Qilu)
- Deal value: Nearly $120m (milestones + single-digit royalties)
- Focus area: AI-generated small molecules for cardiometabolic targets
- Next steps: Target ID, molecule design/optimisation; Qilu handles dev/commercial
What happened?
Insilico Medicine and Qilu Pharmaceutical announced a strategic partnership on 27 January 2026 to co-develop novel small molecule inhibitors for cardiometabolic diseases using Insilico’s Pharma.AI platform. Insilico handles target identification, design and optimisation; Qilu leads subsequent development and commercialisation, with total value approaching $120m including milestones and royalties.
Why does it matter?
Cardiometabolic diseases drive global morbidity; Insilico’s generative AI accelerates novel target discovery and molecule generation, reducing timelines/costs versus traditional methods. Builds on prior Qilu PandaOmics licensing (2021), validating AI’s role in bridging discovery gaps for large-scale healthspan therapies.
Who’s behind it?
Insilico (clinical-stage AI biotech) powers Pharma.AI end-to-end drug R&D with 30+ assets, 22 preclinical/clinical candidates since 2021. Qilu (China’s top pharma) brings 320+ products, 80+ innovative trials and global reach to 1.5bn patients yearly.
How was it achieved?
Pharma.AI integrates biology/chemistry for hit-to-IND; partnership evolves from Qilu’s 2021 software use to joint R&D on undisclosed cardiometabolic targets, leveraging Insilico’s 8-candidate portfolio unveiled at BIO-Europe.
What’s next?
Insilico delivers optimised candidates; Qilu advances to clinic/market. Insilico expands diversified model (13/20 top pharmas licensed, $2bn+ out-licensing).
What are people saying?
Qilu R&D head Sikang: “Deepening… from software to R&D collaboration… synergy… to address unmet needs.” Insilico CEO Zhavoronkov: “Strategies targeting cardiometabolic… potential for large-scale healthspan extension.”